contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bioporto-q3-2025-solid-us-ngal-test-growth-and-focus-on-new-strategy

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Philip Coombes

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel.

It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets. 

BioPorto

BioPorto delivered Q3 revenue of DKK 10.4m, up 7% YoY, driven primarily by U.S. NGAL Research Use Only (RUO) sales growth, which increased 20% in the quarter. Q3 2025 also saw the first U.S. distributor order of ProNephro AKI™ (NGAL), marking the beginning of commercial rollout in the U.S. pediatric market. Total NGAL sales rose 5% (10% at constant exchange rates), while rest-of-world NGAL sales declined due to a non-recurring large bulk order in Q3 2024. Adjusted EBITDA improved slightly to –DKK 16.8m from –DKK 19.6m last year.

BioPorto delivered Q3 revenue of DKK 10.4m, up 7% YoY, driven primarily by U.S. NGAL Research Use Only (RUO) sales growth, which increased 20% in the quarter. Q3 2025 also saw the first U.S. distributor order of ProNephro AKI&#x2122; (NGAL), marking the beginning of commercial rollout in the U.S. pediatric market. Total NGAL sales rose 5% (10% at constant exchange rates), while rest-of-world NGAL sales declined due to a non-recurring large bulk order in Q3 2024. Adjusted EBITDA improved slightly to &#x2013;DKK 16.8m from &#x2013;DKK 19.6m last year.
Operationally, BioPorto completed patient enrollment for its U.S. adult NGAL cut-off study at the end of October, though data analysis is taking longer than planned. As a result, the company now expects to submit its FDA pre-submission in Q1 2026, with the validation study to begin thereafter. The full adult FDA submission timeline has shifted from end-2026 into H1 2027, with clearance still targeted during 2027, as recently announced in the &#x201c;Forward&#x201d; strategy update, which focuses on building U.S. hospital adoption, progressing toward EU IVDR certification, and expanding the addressable market through 2028. 
BioPorto also strengthened its balance sheet with a fully subscribed private placement of 40.4m shares, raising DKK 43m on 13 November 2025. Funding is now expected to cover operations throughout 2026, supporting the completion of adult clinical milestones and commercial expansion. Management reiterates targets of reaching positive cash flow in H2 2027, 60+ active U.S. hospitals in 2026, and 100+ globally in 2027. The capital raise significantly de-risks the roadmap while leaving a smaller remaining funding gap. 
Guidance for 2025 was maintained following the early November revision: revenue DKK 40-45m and adjusted EBITDA DKK 75&#x2013;80m, with sales expected to remain back-end loaded. Overall, Q3 shows steady commercial progress in the U.S., but the updated clinical timeline and higher investment needs underscore the importance of execution under the new strategy.&#xa0;
To learn more, join the presentation of the Q3 2025 results with BioPorto CFO Niels H&#xf8;y Nielsen at 11:00 CET today. Link: https://www.inderes.dk/videos/bioporto-praesentation-af-q3-2025-resultater
Disclaimer: HC Andersen Capital receives payment from BioPorto for a DigitalIR/Corporate visibility agreement / Philip Coombes 07:37 19/11/2025